AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9091474
Drug: Cyclosporine 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine 3.0 mg/kg per day
Trial: 9091474
Drug: Cyclosporine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine 1.5 mg/kg per day
Trial: 9091474
Drug: Cyclosporine 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine 5.0 mg/kg per day (induction phase)
Trial: 22852580
Drug: BRN-01 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRN-01 tablets (homeopathic medicine containing Actaea racemosa, Arnica montana, Glonoinum, Lachesis mutus, Sanguinaria canadensis)
Trial: 22852580
Drug: BRN-01 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRN-01 tablets
Trial: 20598970
Drug: Implantation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implantation of the subcutaneous cardiac monitor (Reveal XT; Medtronic, Inc, Minneapolis, MN)
Trial: 18606966
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin A (Dysport) treatment
Trial: 8877019
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg nalmefene in young subjects (n=18)
Trial: 8877019
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg nalmefene in elderly subjects (n=11)
Trial: 8877019
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg nalmefene in young subjects (n=8)
Trial: 8877019
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg nalmefene in elderly subjects (n=15)
Trial: 6348635
Drug: Intramuscular vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular vitamin E
Trial: 27652041
Drug: PBC &
RxNorm normalized name: Phenobarbital, Belladonna, and Caffeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBC & RBS herbal medicine
Trial: 25191937
Drug: ICSI/PGS treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICSI/PGS treatment
Trial: 25191937
Drug: Standard ICSI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard ICSI treatment
Trial: 22182496
Drug: Cardiac resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac resynchronization therapy (CRT) with atrioventricular optimization (AVO) via SmartDelay or echocardiography
Trial: 20517484
Drug: Rasagiline (as
RxNorm normalized name: rasagiline (as mesylate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rasagiline (as monotherapy in early PD and adjunctive therapy in advanced PD)
Trial: 12351443
Drug: Insulin treatment
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin treatment (hyperinsulinemic-euglycemic clamps at 1, 2, and 4 mU x min(‐1) x kg(‐1)) for 67 hours
Trial: 10419923
Drug: IFN-ribavirin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-ribavirin (3 MU three times weekly + 1-1.2 g ribavirin daily for 6 months)
Trial: 10419923
Drug: IFN monotherapy
RxNorm normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN monotherapy (3 MU three times weekly for 6 months)
Trial: 7593730
Drug: moclobemide (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: moclobemide (450 mg/day) plus thioridazine (100 mg/day)
Trial: 7593730
Drug: moclobemide (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: moclobemide (450 mg/day) plus placebo
Trial: 2147500
Drug: Cefotetan 1
RxNorm normalized name: cefotetan 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotetan 1 g intravenously
Trial: 6407050
Drug: Bupropion (300-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion (300-600 mg/day)
Trial: 29912723
Drug: Balanced crystalloid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced crystalloid and 0.9% saline solution
Trial: 30345312
Drug: Curcumin-Galactomannoside Complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin-Galactomannoside Complex (CGM) at 250 mg × 2/day for 8 weeks
Trial: 20089009
Drug: Rivastigmine transdermal
RxNorm normalized name: Rivastigmine Transdermal System
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine transdermal patch (4.6 mg/24 hr)
Trial: 27687394
Drug: Mechanical ventilation
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical ventilation parameters with f=9 beats per minute, VT=8 mL/kg, I:E=1:2.0
Trial: 22858430
Drug: Intravenous landiolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous landiolol at 5 μg/kg/min for 3 days (group L)
Trial: 22858430
Drug: Oral bisoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral bisoprolol postoperatively with landiolol (group LB)
Trial: 22858430
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group without beta-blocker therapy (group C)
Trial: 20532141
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab injection (IVBI) 1.25 mg/0.05 mL
Trial: 10388248
Drug: Lidocaine 0.5
RxNorm normalized name: LIDOCAINE 0.5% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 0.5 mg/kg/h
Trial: 10388248
Drug: Lidocaine 2.5
RxNorm normalized name: LIDOCAINE 2.5% OINT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 2.5 mg/kg/h
Trial: 8739822
Drug: Quinidine bisulphate
RxNorm normalized name: quinidine bisulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine bisulphate (250 mg)
Trial: 8739822
Drug: Chlorpromazine hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Chlorpromazine (DB00477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorpromazine hydrochloride (100 mg) with quinidine
Trial: 8739822
Drug: Chlorpromazine hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Chlorpromazine (DB00477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorpromazine hydrochloride (100 mg) without quinidine (control)
Trial: 6129367
Drug: Sodium DL‐3‐hydroxybutyrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium DL‐3‐hydroxybutyrate administered during a 2.5 MJ (600 kcal) diet with 34 g protein and total fast (water and vitamins only) on alternate days for 21 days
Trial: 6129367
Drug: Sodium DL‐3‐hydroxybutyrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium DL‐3‐hydroxybutyrate administered during therapeutic starvation for 14 days
Trial: 1902657
Drug: Crystalloid solutions
RxNorm normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crystalloid solutions
Trial: 23842041
Drug: Sunitinib therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib therapy
Trial: 24471663
Drug: Intravenous paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous paracetamol 2 g
Trial: 16508386
Drug: Intravenous parecoxib
RxNorm normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Intravenous parecoxib 40 mg
Trial: 24471663
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of intravenous paracetamol 2 g and intravenous parecoxib 40 mg
Trial: 22937736
Drug: Amoxicillin‐clavulanic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin‐clavulanic acid (22.5 mg/kg twice daily) with placebo‐azithromycin
Trial: 22937736
Drug: Azithromycin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (5 mg/kg daily) with placebo‐amoxicillin‐clavulanic acid
Trial: 22937736
Drug: Placebo‐azithromycin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo‐azithromycin with placebo‐amoxicillin‐clavulanic acid
Trial: 19895619
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for major depression over 18 months
Trial: 19895619
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for major depression
Trial: 18093298
Drug: Passive movement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive movement therapy (PMT) given three times a week for four weeks.
Trial: 16253086
Drug: Chlorhexidine (CHX)
RxNorm normalized name: chlorhexidine gluconate Topical Solution [CHX Plus]
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine (CHX) spray
Trial: 16253086
Drug: Benzydamine hydrochloride
RxNorm normalized name: benzydamine hydrochloride
DrugBank: Benzydamine (DB09084)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzydamine hydrochloride (B‐HCl) spray
Trial: 16253086
Drug: Chlorhexidine plus
RxNorm normalized name: chlorhexidine Topical Solution [CHX Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine plus Benzydamine hydrochloride (CHX/B‐HCl) spray
Trial: 9701431
Drug: Metered Dose
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metered Dose Inhaler (MDI) with Aerochamber
Trial: 2767766
Drug: Doxycycline 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 0.2 g with 300 ml of fresh milk
Trial: 2767766
Drug: Doxycycline 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 0.2 g with 300 ml of water
Trial: 48832
Drug: Educational programme
RxNorm normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational programme aimed at instructing about hypertension and its treatment
Trial: 15266196
Drug: Psychotherapeutic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotherapeutic treatment
Trial: 19723679
Drug: Pro-juven progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pro-juven progesterone cream, 20 mg twice daily
Trial: 17784896
Drug: Unobserved dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unobserved dosing of buprenorphine-naloxone for 3 months
Trial: 17784896
Drug: Observed dosing
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Observed dosing of buprenorphine-naloxone for 3 months
Trial: 17784896
Drug: Unobserved dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unobserved dosing of buprenorphine-naloxone
Trial: 17784896
Drug: Observed dosing
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Observed dosing of buprenorphine-naloxone
Trial: 15569116
Drug: Bifidobacteria-fermented milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifidobacteria-fermented milk (100 mL/day for 12 weeks)
Trial: 3107115
Drug: Lidocaine (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (loading dose: 3 mg/kg body weight in 10 min; maintenance dose: 1 mg/kg in 20 min)
Trial: 3107115
Drug: Tocainide infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocainide infusion (750 mg in 30 min)
Trial: 3107115
Drug: Tocainide orally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocainide orally (400 to 2,400 mg per day)
Trial: 16194311
Drug: Placebo (glycine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (glycine) (0.5 g.kg(‐1).d(‐1) for 7 days)
Trial: 12668699
Drug: Eplerenone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone (25 mg per day initially, titrated to a maximum of 50 mg per day)
Trial: 8705743
Drug: Sequential argon
RxNorm normalized name: argon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential argon laser and Nd:YAG laser iridotomy
Trial: 1679736
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 6‐methylprednisolone (48 mg daily, tapered) and sulfasalazine (3 g daily) (n = 52)
Trial: 6134042
Drug: Oral bromocriptine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral bromocriptine (1.25 mg)
Trial: 3542346
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of moxalactam 2 g intramuscularly
Trial: 3542346
Drug: Three-dose regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-dose regimen of cefoxitin (2 g intramuscularly on call, followed by 2 g intravenously every six hours for two additional doses)
Trial: 25774090
Drug: Sufentanil target-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil target-controlled infusion (TCI) at 0.1682 ng/ml
Trial: 25774090
Drug: Sufentanil target-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil target-controlled infusion (TCI) at various concentrations (0.19, 0.1809, 0.1723, 0.1641, 0.1563, 0.1489 ng/ml)
Trial: 23062248
Drug: Massage (twice-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage (twice-daily for 4 weeks by licensed massage therapists)
Trial: 23062248
Drug: Control care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control care (twice-daily for 4 weeks)
Trial: 16613928
Drug: i.v. acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. acetaminophen 15 mg kg(‐1)
Trial: 16613928
Drug: i.m. meperidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.m. meperidine 1 mg kg(‐1)
Trial: 8625373
Drug: Calcitonin (Calsynar),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitonin (Calsynar), 100 u., i.m. twice a week for 24 weeks
Trial: 8625373
Drug: Calcitonin (Calsynar),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitonin (Calsynar), 100 u., i.m. twice a week for 24 weeks + oral collagen hydrolysate, 10 g per day for 24 weeks
Trial: 8625373
Drug: Oral collagen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral collagen hydrolysate, 10 g per day for 24 weeks (after calcitonin treatment)
Trial: 1351547
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulphate (8 mmol over 5 min followed by 65 mmol over 24 h)
Trial: 16432050
Drug: Hydrochlorothiazide 50
RxNorm normalized name: hydrochlorothiazide 50 MG
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 50 mg/day
Trial: 3049338
Drug: Hydrochlorothiazide 100
RxNorm normalized name: hydrochlorothiazide 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 100 mg/day
Trial: 2870810
Drug: Hydrochlorothiazide plus
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide Oral Capsule [Hydralazine Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide plus Bevantolol 400 mg/day
Trial: 2870810
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy (Hydrochlorothiazide + Bevantolol)
Trial: 26111953
Drug: EGFRI treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGFRI treatment
Trial: 25653802
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser treatment for 20 sessions of 20 minutes
Trial: 19907299
Drug: 20-G standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-G standard PPV
Trial: 19907299
Drug: 25-G transconjunctival
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25-G transconjunctival sutureless vitrectomy (TSV)
Trial: 19907299
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between 20-G and 25-G groups
Trial: 18631166
Drug: Anaerobic storage
RxNorm normalized name: Peptostreptococcus anaerobius
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anaerobic storage with acidified additive solution (AS) at pH 6.5, rejuvenated at 7 weeks of storage
Trial: 18631166
Drug: Anaerobic storage
RxNorm normalized name: Peptostreptococcus anaerobius
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anaerobic storage with acidified additive solution (AS) at pH 6.5, rejuvenated at 11 weeks of storage
Trial: 16144170
Drug: Intraventricular administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraventricular administration of rt-PA (3 mg every 24 hours)
Trial: 16144170
Drug: Intraventricular administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraventricular administration of rt-PA
Trial: 12361993
Drug: Lumbar support
RxNorm normalized name: lumbar supports
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumbar support used daily for the first week and on LBP days for the following 6 months
Trial: 356240
Drug: Proquazone (3x300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proquazone (3x300 mg/day)
Trial: 356240
Drug: Naproxen (2x250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen (2x250 mg plus one placebo capsule/day)
Trial: 30428474
Drug: Rifaximin 550
RxNorm normalized name: rifAXIMin 550 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin 550 mg bid for 3 months
Trial: 30428474
Drug: Rifaximin 550
RxNorm normalized name: rifAXIMin 550 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin 550 mg bid combined with lactulose 30-60 mL daily for 3 months
Trial: 30428474
Drug: Rifaximin therapy
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifaximin therapy with and without lactulose
Trial: 30428474
Drug: Rifaximin therapy
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifaximin therapy
Trial: 30218387
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with house dust mite (HDM) allergen extract
Trial: 23295594
Drug: Brazilian Cardioprotective
RxNorm normalized name: BRAZILIAN PEPPER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brazilian Cardioprotective Diet Program (weekly sessions with dietitians)
Trial: 23295594
Drug: Usual dietary
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Usual dietary therapy (Group B - weekly sessions with dietitian)
Trial: 23295594
Drug: Usual dietary
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Usual dietary therapy (Group C - monthly sessions with dietitian)
Trial: 19531257
Drug: Whole-meal rye
RxNorm normalized name: Rye
DrugBank: Rye (DB10564)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-meal rye bread (150 g)
Trial: 19531257
Drug: White wheat
RxNorm normalized name: WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White wheat bread (150 g)
Trial: 11808763
Drug: Sugar-free chewing
RxNorm normalized name: Equate Nicotine Polacrilex 2mg Sugar-Free Chewing Gum (Fruit)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar-free chewing gum containing 0.19 mg of CPP-ACP
Trial: 11808763
Drug: Sugar-free chewing
RxNorm normalized name: Equate Nicotine Polacrilex 2mg Sugar-Free Chewing Gum (Fruit)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar-free chewing gum containing 10.0 mg of CPP-ACP
Trial: 11808763
Drug: Sugar-free chewing
RxNorm normalized name: Equate Nicotine Polacrilex 2mg Sugar-Free Chewing Gum (Fruit)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar-free chewing gum containing 18.8 mg of CPP-ACP
Trial: 11808763
Drug: Sugar-free chewing
RxNorm normalized name: Equate Nicotine Polacrilex 2mg Sugar-Free Chewing Gum (Fruit)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar-free chewing gum containing 56.4 mg of CPP-ACP
Trial: 7832578
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g elemental calcium (control)
Trial: 7832578
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g elemental calcium
Trial: 7832578
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g elemental calcium
Trial: 8817407
Drug: Nifedipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (10 mg, sublingual)
Trial: 27172664
Drug: Skin wound
RxNorm normalized name: POLOXAMER 188 200 mg in 1 mL TOPICAL LIQUID [Shur Clens Skin Wound Cleanser 24 Count Single Dose Ampules]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin wound induction gel
Trial: 15679765
Drug: Wireless pH
RxNorm normalized name: PH-284
DrugBank: PH-284 (DB05452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wireless pH capsule
Trial: 7717486
Drug: Pethidine (0.85
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pethidine (0.85 mg.kg‐1)
Trial: 7717486
Drug: Lignocaine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine (1 mg.kg‐1)
Trial: 1972833
Drug: PUVA photochemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUVA photochemotherapy (oral 8‐MOP followed by UV‐A from Philips TL‐09)
Trial: 381921
Drug: Piadar lotion,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piadar lotion, applied 2 to 3 times daily for four weeks
Trial: 381921
Drug: Tolnaftate solution,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolnaftate solution, applied 2 to 3 times daily for four weeks